Journal
JOURNAL OF CLINICAL GASTROENTEROLOGY
Volume 39, Issue 4, Pages S131-S137Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mcg.0000155513.17715.f7
Keywords
hepatic venous pressure gradient; hepatic vascular tone; cirrhosis; nitric oxide; vasoactive mediators
Categories
Ask authors/readers for more resources
Increased resistance to portal blood flow is the primary factor in the pathophysiology of portal hypertension, and is mainly determined by the morphologic changes occurring in chronic liver diseases. This is aggravated by an increased hepatic vascular tone, which results from an insufficient hepatic bioavailability of nitric oxide (NO) and an increased production of circulating and local vasoconstrictors (angiotensin, endothelin, cysteinyl-leukotrienes, and thromboxane, among others). This dynamic and reversible component provides the rationale for the use of therapies aimed at decreasing portal pressure by reducing the vascular tone. Among them, systemic and liver-selective NO donors, statins, and gene therapy with adenovirus encoding NO synthases have been used to increase NO availability with promising results. Other attempts have been the blockade of the effect of vasoconstrictors, using anti alpha-adrenergic agents and renin-angiotensin system blockers. Some of these pharmacologic approaches have already been incorporated into clinical practice while others are still under investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available